Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05176626 · ClinicalTrials.gov registry record · Phase 4
Long-term Effectiveness of the Antiobesity Medication Phentermine
A Phase 4 study of Obesity and Lifestyle, Healthy, sponsored by Wake Forest University Health Sciences.
- Active
- Registry status
- Phase 4
- Development phase
- 870
- Enrollment target
- 4
- Study locations
NCT05176626 is a Phase 4 study of Obesity and Lifestyle, Healthy that is active but no longer recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 870 participants, roughly in line with the 818-participant average among 1,053 other Obesity trials with a reported enrollment target. The trial reports 4 study locations across 4 states.
The verdict
NCT05176626, a Phase 4 study of Obesity and Lifestyle, Healthy, is active but no longer recruiting, sponsored by Wake Forest University Health Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 870 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this research study is to understand the long-term effects of the drug phentermine on weight, blood pressure, other health outcomes, and safety. Phentermine has been approved by the US Food and Drug Administration (FDA) for weight management since 1959, but it has not been approved for long-term use (i.e., treatment lasting more than 12 weeks). This trial is designed to learn about the long-term effects of phentermine for up to 2 years because obesity is a chronic disease and expert guidelines recommend long-term use of anti-obesity medications as one treatment option.
Conditions Studied
Interventions
- BEHAVIORAL Online Lifestyle Behavioral Therapy
- DRUG Phentermine Hydrochloride 8 MG
Study Locations (4)
California
- Kaiser Permanente Southern California - Los Angeles
Minnesota
- HealthPartners Institute - Saint Louis Park
North Carolina
- Atrium Health Wake Forest Baptist Weight Management Center - Winston-Salem
Texas
- UT Center for Obesity Medicine and Metabolic Performance - Bellaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 870 participants |
| Start Date | 2022-06-30 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05176626
The ClinicalTrials.gov registry entry for NCT05176626 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 870 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 818-participant average among 1,053 other Obesity trials with a reported enrollment target. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Online Lifestyle Behavioral Therapy is the first listed.
NCT05176626 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Minnesota, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05176626 about?
NCT05176626 is a clinical study titled "Long-term Effectiveness of the Antiobesity Medication Phentermine". The purpose of this research study is to understand the long-term effects of the drug phentermine on weight, blood pressure, other health outcomes, and safety. Phentermine has been approved by the US Food and Drug Administration (FDA) for weight management since 1959, but it has not been approved fo...
What is the current status of trial NCT05176626?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 870 participants. The study started on 2022-06-30. Estimated completion is 2026-12-31.
What conditions does trial NCT05176626 study?
This clinical trial studies the following conditions: Obesity, Lifestyle, Healthy, Obesity; Drug.
What interventions are being tested in trial NCT05176626?
The interventions under investigation include: Online Lifestyle Behavioral Therapy (BEHAVIORAL), Phentermine Hydrochloride 8 MG (DRUG).
Who is sponsoring clinical trial NCT05176626?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05176626 being conducted?
This trial has 4 study locations across California, Minnesota, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
RECRUITING · Phase 4
-
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
RECRUITING · Phase 4
-
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
RECRUITING · Phase 4
-
Fibrosis Lessens After Metabolic Surgery
RECRUITING · Phase 4
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.